Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Darazam
  NCT04521400		 RCThigh-dose IFN beta-1aIFN beta-1aCOVID 19 hospitalizedsome concern
83/85 inconclusive
    SOLIDARITY (interferon)
          NCT04315948    		 RCTIFN beta-1acontrolCOVID 19 hospitalizedsome concern
    		2063/2064 inconclusive
    • inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 severe or critically meta-analysis

    Kalil (ACTT-3)
          NCT04492475    		 RCTIFN beta-1aplaceboCOVID-19 severe or criticallysome concern
    		487/482 inconclusive
    • inconclusive 1 % decrease in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    Davoudi-Monfared
          IRCT20100228003449N2    		 RCTIFN beta-1astandard of careCOVID-19 severe or criticallyhigh
    		46/46 suggested
    • suggested 70 % decrease in death D28 but with a low degree of certainty due to high risk of bias
    • suggested 63 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
    • inconclusive 10 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons